Literature DB >> 32991255

Improved Anti-Prion Nucleic Acid Aptamers by Incorporation of Chemical Modifications.

Jussara Amato1, Tsukasa Mashima2,3, Yuji O Kamatari4, Kazuo Kuwata5, Ettore Novellino1, Antonio Randazzo1, Concetta Giancola1, Masato Katahira2,3, Bruno Pagano1.   

Abstract

Nucleic acid aptamers are innovative and promising candidates to block the hallmark event in the prion diseases, that is the conversion of prion protein (PrP) into an abnormal form; however, they need chemical modifications for effective therapeutic activity. This communication reports on the development and biophysical characterization of a small library of chemically modified G-quadruplex-forming aptamers targeting the cellular PrP and the evaluation of their anti-prion activity. The results show the possibility of enhancing anti-prion aptamer properties through straightforward modifications.

Entities:  

Keywords:  G-quadruplex; aptamers; chemical modifications; prion protein

Year:  2020        PMID: 32991255     DOI: 10.1089/nat.2020.0899

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  3 in total

Review 1.  Therapeutic development of polymers for prion disease.

Authors:  Kenta Teruya; Katsumi Doh-Ura
Journal:  Cell Tissue Res       Date:  2022-03-21       Impact factor: 5.249

2.  KRAS Promoter G-Quadruplexes from Sequences of Different Length: A Physicochemical Study.

Authors:  Federica D'Aria; Bruno Pagano; Luigi Petraccone; Concetta Giancola
Journal:  Int J Mol Sci       Date:  2021-01-05       Impact factor: 5.923

3.  Balancing Affinity, Selectivity, and Cytotoxicity of Hydrazone-Based G-Quadruplex Ligands for Activation of Interferon β Genes in Cancer Cells.

Authors:  Simona Marzano; Giulia Miglietta; Rita Morigi; Jessica Marinello; Andrea Arleo; Monica Procacci; Alessandra Locatelli; Alberto Leoni; Bruno Pagano; Antonio Randazzo; Jussara Amato; Giovanni Capranico
Journal:  J Med Chem       Date:  2022-09-08       Impact factor: 8.039

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.